Ratings Baxter International Inc. Berne S.E.

Equities

BAX

US0718131099

Delayed Berne S.E. Other stock markets 12:00:00 2023-04-06 EDT			5-day change	1st Jan Change
38.11 ^CHF	+3.50%		-.--%	-.--%

06-20	Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors	CI
06-12	Transcript : Baxter International Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM

Strengths

The company has a low valuation given the cash flows generated by its activity.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's earnings growth outlook lacks momentum and is a weakness.
One of the major weak points of the company is its financial situation.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
BAXTER INTERNATIONAL INC.	-.--%	17.08B	-
ABBOTT LABORATORIES	-5.31%	182B	C+
MEDTRONIC PLC	-4.42%	102B	C
BECTON, DICKINSON AND COMPANY	-4.75%	66.74B	A
DEXCOM, INC.	-8.09%	45.55B	B-
CENCORA, INC.	+10.31%	44.89B	B-
HOYA CORPORATION	+6.13%	40.62B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+17.51%	30.04B	B
TERUMO CORPORATION	+14.80%	24.34B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.58%	23.95B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes